Sage Surges After Postpartum Drug Meets Goals in Small Trial

  • Stock up as much as 48%, highest level since January
  • Postive results in mid-stage trial for leading drug candidate

Sage Therapeutics Inc. surged to its highest price in more than six months after reporting positive results for its leading drug candidate in a mid-stage clinical trial for the treatment of severe postpartum depression.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.